Want to see HK:2185 full AI Analyst Report?
2185 Stock Chart & Stats
HK$5.71
HK$0.03(1.94%)
At close: 4:00 PM EST
HK$5.71
HK$0.03(1.94%)
Day’s Range― - ―
52-Week RangeHK$1.82 - HK$9.26
Previous CloseN/A
Volume27.00K
Average Volume (3M)2.14M
Market Cap
HK$552.56M
Enterprise ValueHK$539.00
Total Cash (Recent Filing)HK$248.63M
Total Debt (Recent Filing)HK$12.73M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding235,703,410
10 Day Avg. Volume3,698,147
30 Day Avg. Volume2,141,365
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)2.91
Price to Sales (P/S)28.92
P/FCF Ratio-17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt load gives the company durable financial flexibility to fund R&D, clinical development, or near-term operational needs without high interest obligations. Over 2–6 months this reduces insolvency risk and enables strategic options (partnering or measured capital raises).
Revenue Rebound In 2025A meaningful top-line rebound from a near-zero base signals commercial traction or successful product/commercial initiatives. If revenues continue to scale, that trend provides a structural path toward margin leverage and less reliance on external financing over several quarters.
Improving Cashflow TrajectoryAlthough cash flow remains negative, a clear improvement trajectory suggests operational fixes or better revenue conversion. Sustained improvement in operating cash flow can materially reduce financing frequency and stabilize operations over the medium term if execution continues.
Bears Say
Negative ProfitabilityPersistent negative gross margins and large operating losses indicate the business has not yet proven a sustainable profit model. Over months this limits the company's ability to self-fund growth, undermines reinvestment capacity, and increases dependence on external capital or strategic partnerships.
Ongoing Cash BurnConsistent negative operating and free cash flow mean the company must repeatedly access capital markets or partners to operate. That reliance creates dilution risk and execution pressure; if funding conditions tighten, meeting near-term obligations and sustaining development programs could be at risk.
Eroding Equity And Negative ROEDeclining equity and negative ROE show cumulative losses are eroding the capital base, reducing financial resilience. Over a multi-month horizon this weakens borrowing capacity, raises the chance of more dilutive raises, and limits strategic flexibility for partnerships or M&A.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H News
2185 FAQ
What was Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H lowest stock price was HK$1.82 and its highest was HK$9.26 in the past 12 months.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap is HK$552.56M.
When is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Mar 26, 2027 which is in 210 days.
How were Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H released its earnings results on Aug 26, 2026. The company reported -HK$0.153 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H have?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 235,703,410 shares outstanding.
What happened to Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H reported an EPS of -HK$0.153 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shanghai Bio-Heart Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.74%
Trailing 12-Months
Company Description
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) Earnings & Revenues
Technical Analysis
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Wuhan YZY Biopharma Co., Ltd. Class H
―
Sunho Biologics,Inc.
―